Actualités thérapeutiques dans la thrombocytémie essentielle

Essential thrombocythemia is a myeloproliferative disorder affecting megakaryocyte and is characterized by frequent thrombotic or hemorrhagic complications. In young patients, the optimal management of thrombocythaemia is controversial. Since th relationship of thrombosis and hemorrhage to platelet counts is not demonstrated, ther is no clear inidcation for using drugs capable of lowering platelet counts in young asymptomatic subjects. However, treatment should be offered to patients with a definite high risk of major or life-threatening hemostatic complications. The present paper reviews the incidence and risk factors for thrombotic complications and the use of medications inhibiting platelet production.